Gene editing stocks get bushwhacked as new studies highlight CRISPR/Cas9 cancer risks
Gene editing stocks have a habit of running up and down when some new piece of research underscores their potential or the risks associated with the tech.
Today the numbers were plunging into the red for CRISPR Therapeutics $CRSP, Intellia $NTLA and Editas $EDIT as some top-level investigators spotlighted a connection between CRISPR-Cas9 and an added risk of cancer associated with the technology. And soon after the studies hit, the biotechs involved began to strike back at the researchers’ conclusions.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters